论文信息 - BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma - 字舞流文

BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma

A. Ferrari | YounJeong Choi | J. Chisholm | M. Das Thakur | I. Dunkel | M. Casanova | Weijiang Zhang | S. Simko | Jozef Suvada | Natasha Ritchie | Jane Park | Nga Wan Rachel Tam